Across the SURMOUNT-1 obesity trial and the product label, tirzepatide's adverse reactions are predominantly gastrointestinal: nausea, diarrhea, vomiting, constipation, abdominal pain, and dyspepsia. They are mostly mild to moderate and cluster during the dose-escalation period.[1][2][3]
Reviewed for accuracy · Last reviewed July 7, 2026The label also carries a boxed warning for thyroid C-cell tumors and lists it as contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Independently sourced vials are the same molecule but carry no guarantee of the purity or accuracy testing a regulated product does, which adds its own uncertainty.
Gastrointestinal effects most often show up right after a step-up. Holding a dose steady rather than escalating on schedule, and eating smaller lighter meals, are commonly discussed ways to make them more tolerable.
This page is an independent educational reference and is not medical advice. Talk to a doctor before starting or adjusting any compound.